pembrolizumab,vibostolimab,favezelimab
merck
['mibc', 'pembro', 'key,note,57', 'nmibc']
 presented data for cohort b of keynote-057. about 30% of patients had long-term control of disease and avoid radical cystectomy. is this a sufficient result to offer this strategy?#ascogu23 
Associate Profesor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy. Focused on GU cancers. Husband & father of 2 kids.